000182814 001__ 182814
000182814 005__ 20240229145732.0
000182814 0247_ $$2doi$$a10.1016/j.radonc.2022.11.015
000182814 0247_ $$2pmid$$apmid:36442608
000182814 0247_ $$2ISSN$$a0167-8140
000182814 0247_ $$2ISSN$$a1879-0887
000182814 0247_ $$2altmetric$$aaltmetric:139941361
000182814 037__ $$aDKFZ-2022-02946
000182814 041__ $$aEnglish
000182814 082__ $$a610
000182814 1001_ $$0P:(DE-He78)dd2a4cfd38fcbd0112e8b6cb387b6753$$aHeumann, Philipp$$b0$$eFirst author$$udkfz
000182814 245__ $$aComparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study.
000182814 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2023
000182814 3367_ $$2DRIVER$$aarticle
000182814 3367_ $$2DataCite$$aOutput Types/Journal article
000182814 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1673509868_7010
000182814 3367_ $$2BibTeX$$aARTICLE
000182814 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182814 3367_ $$00$$2EndNote$$aJournal Article
000182814 500__ $$a#EA:C020#LA:C020# / Volume 178, January 2023, 109426
000182814 520__ $$aPrevious studies showed that healthcare professionals and patients had only moderate to low agreement on their assessment of treatment-related symptoms. We aimed to determine the levels of agreement in a large cohort of prostate cancer patients.Analyses were made of data from 1,756 prostate cancer patients treated with external beam radiotherapy (RT) and/or brachytherapy in Europe and the USA and recruited into the prospective multicentre observational REQUITE study. Eleven pelvic symptoms at the end of RT were compared after translating patient-reported outcomes (PROs) into CTCAE-based healthcare professional ratings. Gwet's AC2 agreement coefficient and 95% confidence intervals were calculated for each symptom. To compare severity of grading between patients and healthcare professionals, percent agreement and deviations for each symptom were graphically depicted. Stratified and sensitivity analyses were conducted to identify potential influencing factors and to assess heterogeneity and robustness of results.The agreement for the 11 pelvic symptoms varied from very good (AC2>0.8: haematuria, rectal bleeding, management of sphincter control) to poor agreement (AC2≤0.2: urinary frequency fair, proctitis and urinary urgency). Fatigue had a negative impact on the agreement. Patients tended to grade symptoms more severely than healthcare professionals. Information on sexual dysfunction was missing more frequently in healthcare professional assessment than PROs.Agreement was better for observable than subjective symptoms, with patients usually grading symptoms more severely than healthcare professionals. Our findings emphasize that PROs should complement symptom assessment by healthcare professionals and be taken into consideration for clinical decision-making to incorporate the patient perspective.
000182814 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000182814 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182814 650_7 $$2Other$$aadverse events
000182814 650_7 $$2Other$$aagreement
000182814 650_7 $$2Other$$apatient-reported outcomes
000182814 650_7 $$2Other$$aprostate cancer
000182814 650_7 $$2Other$$aradiotherapy
000182814 7001_ $$aAguado-Barrera, Miguel E$$b1
000182814 7001_ $$aAvuzzi, Barbara$$b2
000182814 7001_ $$aAzria, David$$b3
000182814 7001_ $$aBriers, Erik$$b4
000182814 7001_ $$aBultijnck, Renée$$b5
000182814 7001_ $$aChoudhury, Ananya$$b6
000182814 7001_ $$aDe Ruysscher, Dirk$$b7
000182814 7001_ $$aFarcy-Jacquet, Marie-Pierre$$b8
000182814 7001_ $$aFonteyne, Valérie$$b9
000182814 7001_ $$aGómez Caamaño, Antonio$$b10
000182814 7001_ $$0P:(DE-He78)6463d23a85ce9e7ecc93b32fc2b4d25f$$aHelmbold, Irmgard$$b11$$udkfz
000182814 7001_ $$aJohnson, Kerstie$$b12
000182814 7001_ $$aKerns, Sarah L$$b13
000182814 7001_ $$aLambrecht, Maarten$$b14
000182814 7001_ $$aLingard, Zoe$$b15
000182814 7001_ $$aRancati, Tiziana$$b16
000182814 7001_ $$aRosenstein, Barry$$b17
000182814 7001_ $$aSperk, Elena$$b18
000182814 7001_ $$aPaul Symonds, R.$$b19
000182814 7001_ $$aTalbot, Christopher$$b20
000182814 7001_ $$aValdagni, Riccardo$$b21
000182814 7001_ $$aVega, Ana$$b22
000182814 7001_ $$aVeldeman, Liv$$b23
000182814 7001_ $$aWard, Tim$$b24
000182814 7001_ $$aWebb, Adam$$b25
000182814 7001_ $$aWest, Catharine$$b26
000182814 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b27$$udkfz
000182814 7001_ $$0P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aSeibold, Petra$$b28$$eLast author$$udkfz
000182814 7001_ $$aConsortium, REQUITE$$b29$$eCollaboration Author
000182814 773__ $$0PERI:(DE-600)1500707-8$$a10.1016/j.radonc.2022.11.015$$gp. S0167814022045637$$p109426$$tRadiotherapy and oncology$$v178$$x0167-8140$$y2023
000182814 909CO $$ooai:inrepo02.dkfz.de:182814$$pVDB
000182814 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)dd2a4cfd38fcbd0112e8b6cb387b6753$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000182814 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6463d23a85ce9e7ecc93b32fc2b4d25f$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000182814 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b27$$kDKFZ
000182814 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aDeutsches Krebsforschungszentrum$$b28$$kDKFZ
000182814 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000182814 9141_ $$y2022
000182814 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-31
000182814 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-31
000182814 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-31
000182814 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000182814 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOTHER ONCOL : 2022$$d2023-10-21
000182814 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000182814 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000182814 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000182814 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000182814 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000182814 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000182814 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000182814 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000182814 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bRADIOTHER ONCOL : 2022$$d2023-10-21
000182814 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000182814 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000182814 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000182814 980__ $$ajournal
000182814 980__ $$aVDB
000182814 980__ $$aI:(DE-He78)C020-20160331
000182814 980__ $$aUNRESTRICTED